GPC3 and neoplasm: In efforts to enhance NK cell-mediated tumor responses, a recent study introduced antibody-based therapies known as NK cell engagers (NKCEs), specifically targeting Glypican-3 (GPC3) in HCC (Arulanandam et al., 2023).